Medical Condition News

RSS

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Two-year trial to test effectiveness of behavioral psychotherapy for young adolescents with autism

The USF Health Rothman Center for Neuropsychiatry in St. Petersburg, FL, is conducting a two-year federal trial testing the effectiveness of behavioral psychotherapy in treating anxiety among young adolescents with autism.

28 Oct 2009

Debilitating muscle weakness can linger long after hospital discharge

After decades of focusing on the management of respiratory failure, circulatory shock and severe infections that lead to extended stays in hospital intensive care units, critical care researchers are increasingly turning attention to what they believe is a treatable complication developed by many who spend days or weeks confined to an ICU bed: debilitating muscle weakness that can linger long after hospital discharge.

28 Oct 2009

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

28 Oct 2009

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

28 Oct 2009

Noncardiovascular mortality are rates higher in patients receiving dialysis

Compared to the general population, patients starting dialysis have an increased risk of death that is not attributable to a higher rate of death from cardiovascular causes, as previously thought, according to a study in the October 28 issue of JAMA.

28 Oct 2009

IFPA urges WHO to act on new insights on psoriasis to help millions of psoriasis patients

October 29 is World Psoriasis Day. Conceived by patients for patients, World Psoriasis Day is a truly global event focusing on the burden of living with psoriasis. There are more than 125 million people with psoriasis/psoriatic arthritis in the world. Psoriasis is a severe chronic inflammatory disease that effects all ages, genders, races and ethnicities.

28 Oct 2009

Shire receives European approval for FOSRENOL

Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

28 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

NBPF develops 'Safe 'til Stable' preventative care program for bipolar disorder patients

A major breakthrough in mental health has been developed, a cooperative venture between the National Bipolar Foundation and the MedicAlert Foundation; a preventative care program called "Safe 'til Stable." It provides vital medical information to emergency responders in time of need through our live 24-hour emergency response service.

28 Oct 2009

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

28 Oct 2009

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent and Trademark Office covering vitamin receptor binding anti-cancer agents.

28 Oct 2009

Dementia patients face higher risk of flu mortality; refine guidelines needed for testing and vaccination policies

An epidemiological study on pneumonia and influenza (P&I) in adults age 65 and over reports that patients with dementia are diagnosed with flu less frequently, have shorter hospital stays, and have a fifty percent higher rate of death than those without dementia.

28 Oct 2009

Contour Products promotes the results of a 2009 survey conducted among respiratory therapists

In conjunction with National Respiratory Care Week, Contour Products(TM), a leader in the sleep support and comfort industry, is proud to promote the results of a 2009 survey conducted among respiratory therapists who work with CPAP patients daily. One of the most common issues among CPAP therapy users is discomfort when sleeping with their CPAP mask, as a result of the mask pressing against their face.

28 Oct 2009

Culture-based treatment may be effective for reducing depression

A genetic tendency to depression is much less likely to be realized in a culture centered on collectivistic rather than individualistic values, according to a new Northwestern University study.

28 Oct 2009

Dr. Jay Smith receives PASSOR Legacy Award and Lectureship from AAPM&R

The American Academy of Physical Medicine and Rehabilitation (AAPM&R) awarded Jay Smith, M.D., of Mayo Clinic's Department of Physical Medicine and Rehabilitation, the Physiatric Association of Spine, Sports and Occupational Rehabilitation (PASSOR) Legacy Award and Lectureship.

28 Oct 2009

National Institutes of Health awards $735,000 grant for prenatal obesity and diabetes research

The National Institutes of Health has awarded Clemson University professor Maria Mayorga and Medical University of South Carolina professor Kelly Hunt a $735,000 grant to study the effects of a mother's obesity and diabetes on infant health in certain ethnic groups.

28 Oct 2009

Medical Condition News

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Two-year trial to test effectiveness of behavioral psychotherapy for young adolescents with autism

Debilitating muscle weakness can linger long after hospital discharge

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

Noncardiovascular mortality are rates higher in patients receiving dialysis

IFPA urges WHO to act on new insights on psoriasis to help millions of psoriasis patients

Shire receives European approval for FOSRENOL

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

NBPF develops 'Safe 'til Stable' preventative care program for bipolar disorder patients

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Dementia patients face higher risk of flu mortality; refine guidelines needed for testing and vaccination policies

Contour Products promotes the results of a 2009 survey conducted among respiratory therapists

Culture-based treatment may be effective for reducing depression

Dr. Jay Smith receives PASSOR Legacy Award and Lectureship from AAPM&R

National Institutes of Health awards $735,000 grant for prenatal obesity and diabetes research

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News